Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
Frontiers in Pharmacology · 03.03.2023 · 14
DOI: 10.3389/fphar.2023.1124214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.03.2023. Verfasst von Can G Leineweber und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department B, Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology, and Diabetes, Brandenburg Medic…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a leading cause of cancer death, and medical treatment options are limited. The multikinase inhibitor sorafenib was the first approved drug widely used for systemic therapy in advanced HCC. Sorafenib might affect polyunsaturated fatty acids (PUFA)-derived epoxygenated metabolite levels, as it is also a potent inhibitor of the soluble epoxide hydrolase (sEH), which catalyzes the conversion of cytochrome-P450 (CYP)-derived epoxide metabolites derived from PUFA, such as omega-6 arachidonic acid (AA) and omega-3 docosahexaenoic acid (DHA), into their corresponding dihydroxy metabolites. Experimental studies with AA-derived epoxyeicosatrienoic acids (EETs) have shown that they can promote tumor growth and metastasis, while DHA-derived 19,20-epoxydocosapentaenoic acid (19,20-EDP) was shown to have anti-tumor activity in mice. In this study, we found a significant increase in EET levels in 43 HCC patients treated with sorafenib and a trend towards increased levels of DHA-derived 19,20-EDP. We demonstrate that the effect of sorafenib on CYP- metabolites led to an increase of 19,20-EDP and its dihydroxy metabolite, whereas DHA plasma levels decreased under sorafenib treatment. These data indicate that specific supplementation with DHA could be used to increase levels of the epoxy compound 19,20-EDP with potential anti-tumor activity in HCC patients receiving sorafenib therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Department B, Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology, and Diabetes, Brandenburg Medical School, University Hospital Ruppin-Brandenburg, Neuruppin, Germany.
- Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology, Brandenburg Medical School and University of Potsdam, Potsdam, Germany.
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
- Lipidomix, Berlin, Germany.
- Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Magdeburg, Germany.
Zitieren
APA
Leineweber, C. G., Rabehl, M., Pietzner, A., Rohwer, N., Rothe, M., Pech, M., Sangro, B., Sharma, R., Verslype, C., Basu, B., Sengel, C., Ricke, J., Schebb, N. H., Weylandt, K. H., & Benckert, J. (2023). Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1124214
Vancouver
Leineweber CG, Rabehl M, Pietzner A, Rohwer N, Rothe M, Pech M, et al. Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1124214
BibTeX
@article{Leineweber2023,
author = {Leineweber, Can G and Rabehl, Miriam and Pietzner, Anne and Rohwer, Nadine and Rothe, Michael and Pech, Maciej and Sangro, Bruno and Sharma, Rohini and Verslype, Chris and Basu, Bristi and Sengel, Christian and Ricke, Jens and Schebb, Nils Helge and Weylandt, Karsten-H and Benckert, Julia},
title = {Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1124214}
}
EUVIMED